Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

634
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
634
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

751
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

547
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
547
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

520
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

697
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Market Analysis of the Xenios Console With the Xlung Tubing Kit 230 for Extracorporeal Membrane Oxygenation After Cardiac Surgery.

Artificial organs·2026
Same author

The choice of mitral valve surgery type and mid-term outcomes in patients up to 70 years of age: Results of the AUTHEARTVISIT study.

JTCVS open·2026
Same author

Large Mitral Annuli in Transcatheter Mitral Valve Replacement: A Marker of Advanced Disease or Limited Benefit?

The Annals of thoracic surgery·2026
Same author

A. Kocher technique as default approach to aortic root enlargement.

JTCVS techniques·2026
Same author

Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.

ESC heart failure·2026
Same author

Association of surgeon sex with postoperative adverse outcomes in adult cardiac surgery: a nationwide cohort study.

Journal of cardiothoracic surgery·2026

Related Experiment Video

Updated: Mar 28, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.

Ivan Netuka1, Poornima Sood2, Yuriy Pya3

  • 1Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Second Department of Surgery, Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

Journal of the American College of Cardiology
|December 17, 2015
PubMed
Summary

The HeartMate 3 left ventricular assist system (LVAS) demonstrates high survival rates and improved quality of life for advanced heart failure patients. This fully magnetically levitated device offers a safe and effective long-term support solution.

Keywords:
HeartMate 3hemolysispumpquality of lifethrombosis

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Related Experiment Videos

Last Updated: Mar 28, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering
  • Medical Devices

Background:

  • The HeartMate 3 left ventricular assist system (LVAS) is designed for long-term support in advanced heart failure.
  • Its centrifugal flow pump features a magnetically levitated rotor for enhanced hemocompatibility and an artificial pulse.

Purpose of the Study:

  • To evaluate the performance and safety of the HeartMate 3 LVAS in a prospective, multicenter study.
  • Assessed 6-month survival against INTERMACS-derived performance goals.

Main Methods:

  • Enrolled 50 adult patients with advanced heart failure (ejection fraction ≤ 25% or inotrope-dependent).
  • Indications included bridge to transplantation (54%) and destination therapy (46%).
  • Primary endpoint: 6-month survival compared to INTERMACS performance goal.

Main Results:

  • Achieved 92% 6-month survival, exceeding the 88% performance goal.
  • Reduced mortality risk by 66% compared to predicted survival (p = 0.0093).
  • Key adverse events: bleeding (14%), driveline infection (10%), GI bleeding (8%), stroke (8%); no pump malfunctions or thrombosis.

Conclusions:

  • The fully magnetically levitated centrifugal-flow LVAS is safe and effective for chronic support.
  • Demonstrated high survival rates, a favorable safety profile, and improved quality of life and functional status.